Orthocell has appointed two experienced US-based executives to drive the market launch and sales of Remplir™ following the expected US FDA approval in the first quarter of 2025.
John Walker joins the team as Vice President – Sales. Mr Walker is a highly experienced sales executive, who has successfully led global product launches and sales strategies, most notably helping to lead the growth of nerve repair device sales at Axogen.
Orthocell also welcomes Phillip Edmondson, Vice President – Medical Affairs. Mr Edmondson is an award-winning medical affairs professional, who excels in creating product awareness, building advocacy and implementing successful medical education programs that contribute to sales growth.
Orthocell CEO and MD, Paul Anderson, said:
“The USA provides a significant opportunity for our company as a circa $US 1.6 billion market, and our belief is that it will quickly become our single largest market…We are delighted to have John and Phillip join us to lead the US launch and are excited about the next phase of growth. With all the preparation we’ve been conducting in the background, we expect revenue growth and surgeon adoption of Remplir to accelerate from market clearance.”
Orthocell remains on schedule to release top-line results from its Remplir US market authorisation study and submit its Remplir US 510(K) application in Q4 CY24.